TNFRSF17 and plasma cell myeloma: The potentiated anti-tumor effects of drug-treated CAR T cells were validated in a leukemia model utilizing NALM6 cells, a multiple myeloma model with BCMA-directed CAR T cells, and a solid tumor model employing GD2-directed CAR T cells against SH-SY5Y neuroblastoma cells (Figures S15B–S15D).